What is Coversyl Plus 4/1.25mg?

Coversyl Plus 4/1.25mg is a prescription fixed-dose combination cardiovascular tablet containing Perindopril erbumine 4mg (ACE inhibitor) and Indapamide 1.25mg (thiazide-like diuretic). Manufactured by Servier Pharma, it provides dual complementary antihypertensive action in a single once-daily tablet. The ADVANCE trial demonstrated that this combination significantly reduced mortality and major macrovascular and microvascular events in patients with type 2 diabetes. Consult your doctor; prescription required.

How Does Coversyl Plus 4/1.25mg Work?

Perindopril (ACE inhibitor): inhibits ACE, blocking conversion of angiotensin I to angiotensin II — reducing vasoconstriction, aldosterone secretion, sodium retention, and cardiac afterload. Also increases bradykinin (accounts for the dry cough side effect). Indapamide (thiazide-like diuretic): sulfonamide-class diuretic with a predominantly vasodilatory action on vascular smooth muscle at therapeutic doses — it has less metabolic disturbance (less impact on glucose, lipids, and uric acid) than classic thiazides like hydrochlorothiazide (HCTZ). At 1.25mg, the antihypertensive effect is primarily through vascular smooth muscle relaxation and mild natriuresis. The complementary ACE inhibition plus diuresis provides additive blood pressure reduction.

Uses of Coversyl Plus 4/1.25mg

Coversyl Plus 4/1.25mg is indicated for: essential hypertension in patients requiring combination antihypertensive therapy; patients with type 2 diabetes and hypertension — the ADVANCE trial showed this specific combination reduced total mortality by 14% and cardiovascular mortality by 18%; and patients already stabilised on perindopril and indapamide as separate tablets, for whom fixed-dose combination simplifies therapy and improves adherence.

Dosage & Administration

One tablet once daily in the morning, preferably before or with a light meal. Swallow whole with a glass of water. Blood pressure and electrolytes (especially potassium and sodium) should be monitored, particularly at initiation and after dose changes. Renal function monitoring is required as for all ACE inhibitors. Do not stop abruptly. Prescription required.

Side Effects

Perindopril-related: dry persistent cough (bradykinin class effect — most common reason for switching to ARB), first-dose hypotension (sit or lie down after first dose), angioedema (rare but serious — facial/throat swelling, stop immediately and seek emergency care), hyperkalaemia, acute kidney injury in susceptible patients. Indapamide-related: hypokalaemia (low potassium — monitor electrolytes; less likely at 1.25mg than higher thiazide doses), mild hyponatraemia, hyperuricaemia (gout flare), photosensitivity. Minimal effect on blood glucose and lipids compared to standard thiazides.

Precautions

Contraindicated in: history of ACE inhibitor angioedema, bilateral renal artery stenosis, pregnancy and breastfeeding, severe renal impairment, severe hepatic impairment, and concomitant sacubitril/valsartan use. Monitor serum potassium, sodium, creatinine, and uric acid at baseline and during treatment. Avoid potassium supplements or potassium-sparing diuretics unless specifically directed — ACE inhibitor already reduces aldosterone, adding a potassium supplement risks hyperkalaemia. Indapamide-related sulfonamide allergy: contraindicated in patients with known sulfonamide hypersensitivity. Prescription required.

Frequently Asked Questions

Q: Why is Coversyl Plus preferred over separate tablets in hypertension?
A: Fixed-dose combinations improve medication adherence — studies consistently show that patients who take one tablet are more likely to continue therapy than those who take two separate pills. Coversyl Plus also offers the proven synergistic antihypertensive effect of perindopril and indapamide.

Q: What is the ADVANCE trial and why does it matter for Coversyl Plus?
A: The ADVANCE trial was a landmark randomised controlled trial in patients with type 2 diabetes. It demonstrated that the perindopril-indapamide combination (Coversyl Plus) significantly reduced total mortality, cardiovascular mortality, and macrovascular/microvascular complications — making it an evidence-based choice for hypertensive patients with diabetes.

Q: Is the indapamide in Coversyl Plus the same as a regular water tablet (diuretic)?
A: Indapamide is a thiazide-like diuretic, but at 1.25mg it acts primarily on vascular smooth muscle rather than the kidneys. It causes less metabolic disturbance (less glucose elevation, lipid changes, or gout) than classic thiazides like hydrochlorothiazide.